Table 3 Baseline characteristics of participants included in this metaanalysis
Study | BEAUTIFUL 2008 | SHIFT 2010 | SIGNIFY 2014 | Study arm | |
|---|---|---|---|---|---|
Ivabradine | Placebo | ||||
Age(mean ± SD) | 65.2(8.5) | 60.4(11.3) | 65(7.2) | 63.7(9) | 63.4(9.1) |
use of B-blockers | |||||
Yes | 9487(87) | 5820(89) | 7939(81) | 5193(86) | 5201(87) |
Male | 9047(83) | 4970(76) | 13,839(72) | 13,951(76.4) | 13,905(76.2) |
Female | 1870(17) | 1535(24) | 5263(28) | 4319(23.6) | 4349(23.8) |
DM status | 4036(37) | 1979(30) | 8230(43) | 7093(38.8) | 7152(39.20) |
Hypertension | 7720(71) | 4314(66) | 16,466(86) | 14,319(78.4) | 14,181(77.7) |
Heart rate(mean ± SD) | 71.5(9.8) | 79.8(9.6) | 77.1(7) | 76(8.7) | 76.3(8.93) |
Previous stroke | 1997(18%) | 526(8) | 1265(6.6) | 627.3(10.9) | 633.3(11.2) |
LVEF,mean(SD),in % | 32.4(5.5) | 29(5.19) | 56.4(8.5) | 39.3(6.4) | 39.3(6.4) |
BMI,kg/m2,mean(SD) | 28.5(4.4) | 28(5) | 28.7(4.6) | 28.4(4.7) | 28.4(4.7) |